Figure 4From: Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study Mean OSDI scores over the course of the study (n = 78). The change in OSDI score (± SE) over time was not statistically significant in either group (P > 0.1). Bim/tim, bimatoprost 0.03% and timolol maleate 0.5%; dorz/brim/tim, dorzolamide 2%, brimonidine 0.2%, and timolol maleate 0.5%; OSDI, Ocular Surface Disease Index; SE, standard error.Back to article page